Britain widens access to Pfizer’s oral antiviral COVID treatment through trial

Britain widens access to Pfizer’s oral antiviral COVID treatment through trial
April 12, 2022, 8:40 am

UK health minister Sajid Javid/Official Facebook page

The Arab News reported, citing Reuters, the UK health ministry said on Tuesday (Apr 12) that the country will expand access to Pfizer’s oral antiviral COVID-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population.

Paxlovid, a combination of Pfizer’s new pill with an older antiviral ritonavir, was made available to thousands of people with compromised immune systems in Britain in February.

Now Paxlovid is being added to the Panoramic national study in England, which is making antivirals available to a wide number of patients while collecting data on how the drugs should best be used in a vaccinated adult population.

According to the report, Paxlovid was shown to reduce the relative risk of death or hospitalization by nearly 90 percent in clinical trials of high risk individuals given the treatment for five days. Currently it is advised to be taken during the early stages of COVID, though last month was added to another trial for hospitalized patients.

UK will expand access to Pfizer’s oral antiviral COVID-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population (File photo: Shutterstock) — Britain will expand access to Pfizer’s oral antiviral COVID-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population (File photo: Shutterstock)

Britain has reported 170,000 deaths from COVID-19, and Prime Minister Boris Johnson has cited antivirals as part of his plan to learn to live with the virus, saying they can cut deaths among those who do not benefit as much from vaccine protection, such as the immunosuppressed.

Queen Elizabeth shares her COVID experience; 'It does leave one very tired and exhausted, doesn't it?'

Health minister Sajid Javid said in a statement: “As we learn to live with COVID, the UK continues to lead the way in using cutting-edge treatments which have already saved the lives of many of the country’s most vulnerable patients."

The report said that the panoramic study is open to adults over age 50, or those aged between 18 and 49 who have underlying health conditions that may put them at higher risk for severe COVID.

It mentioned, Paxlovid is the second antiviral to be added to the trial after molnupiravir, a pill made by Merck & Co. and Ridgeback Biotherapeutics that did not perform as well in its pivotal clinical trial.

Covid vaccines now available for children from five to 11-year olds in England

The health ministry said that 20,000 people had joined the Panoramic study to generate data on molnupiravir, with a further 17,500 people to be enrolled to access Paxlovid.

Source: arabnews

Turkmenistan to shut down Darvaza natural gas crater known by locals as ‘Gateway to Hell’ Official COVID-19 test is no longer needed in Netherlands to confirm infection